Michel Fanny, Folcher Marc
Department of Biosystems Science and Engineering, ETH Zurich, Switzerland.
Porto Biomed J. 2017 Sep-Oct;2(5):145-149. doi: 10.1016/j.pbj.2017.07.001. Epub 2017 Jul 29.
Resort to medications dates back million years ago with the use of medicinal plants. In the nineteenth century, significant contributions in medicine appeared in different domains, among which the invention of a specific drug delivery device; the syringe. Nowadays, injection therapy of bio-manufactured drugs is routine practice for chronic diseases but remains constraining and painful. New emerging advanced therapies invest in genetic, electronics and cell-based therapy for addressing unmet needs for the caregivers and the patient. As digital process in health (eHealth) gains momentum, connected advanced bio-electronic devices now offer new strategies for personalized injection therapies. In this review, we take a journey along the genesis path of a new drug delivery system: the Optogenerapy, a synergy between optogenetic and gene therapy. Inside a bio-electronic implant, electronics and optogenetics are interfaced by light as a traceless inducer signal. By controlling a synthetic optogenetic pathway in the cell, therapeutics delivery can be fine-tuned with a precise spatiotemporal control. The technology holds promise of a new modern syringe era capable of producing a drug of interest at will directly inside the patient.
药物的使用可以追溯到数百万年前,当时人们使用药用植物。在19世纪,医学在不同领域取得了重大进展,其中包括一种特定药物输送装置——注射器的发明。如今,生物制造药物的注射疗法是治疗慢性病的常规做法,但仍然具有局限性且令人痛苦。新兴的先进疗法致力于基因、电子和细胞疗法,以满足护理人员和患者未得到满足的需求。随着健康领域的数字进程(电子健康)蓬勃发展,联网的先进生物电子设备现在为个性化注射疗法提供了新策略。在这篇综述中,我们沿着一种新的药物输送系统——光遗传学疗法的起源路径展开探讨,它是光遗传学和基因疗法的协同作用。在生物电子植入物内部,电子学和光遗传学通过光作为无痕诱导信号进行连接。通过控制细胞中的合成光遗传学通路,可以通过精确的时空控制对治疗药物的输送进行微调。这项技术有望开创一个新的现代注射器时代,能够直接在患者体内按需生产所需药物。